Literature DB >> 19806149

Unanticipated demyelinating pathology of the CNS.

Darin T Okuda1.   

Abstract

Incidentally identified anomalies within the CNS that are highly suggestive of demyelinating disease have been extensively described in neuropathological series, and are increasingly being detected during premortem investigations. With the exception of studies that focused specifically on the prevalence of this entity, the observed anomalies are unanticipated and unrelated to the intended purpose of the examination. The discovery of MRI technology, and its subsequent widespread adoption in the clinic, has facilitated the identification of such cases. The natural course of individuals with incidentally identified demyelinating anomalies is unknown at present. This Review focuses on the history and nosology of unexpected demyelinating pathology, encompassing both autopsy data and MRI-based antemortem investigations of large cohorts, as well as family members at high risk of developing multiple sclerosis. Longitudinal clinical data acquired from prospectively followed cohorts will also be reviewed. In addition, I discuss the estimated prevalence of demyelinating pathology, the currently proposed criteria for its identification, implications for therapeutic intervention, and predictors of disease progression.

Entities:  

Mesh:

Year:  2009        PMID: 19806149     DOI: 10.1038/nrneurol.2009.157

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  33 in total

1.  Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive multiple sclerosis may last 10 years.

Authors:  G V McDonnell; J Cabrera-Gomez; D B Calne; D K B Li; J Oger
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

Review 2.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?

Authors:  Douglas S Goodin
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

3.  Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis.

Authors:  Nicola De Stefano; Eleonora Cocco; Marina Lai; Marco Battaglini; Andrea Spissu; Piernicola Marchi; Gianluca Floris; Marzia Mortilla; Maria L Stromillo; Andrea Paolillo; Antonio Federico; Maria Giovanna Marrosu
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

4.  Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile.

Authors:  C Lebrun; C Bensa; M Debouverie; J De Seze; S Wiertlievski; B Brochet; P Clavelou; D Brassat; P Labauge; E Roullet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02       Impact factor: 10.154

5.  Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis.

Authors:  F Fazekas; H Offenbacher; S Fuchs; R Schmidt; K Niederkorn; S Horner; H Lechner
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

6.  British Isles survey of multiple sclerosis in twins: MRI.

Authors:  J W Thorpe; C J Mumford; D A Compston; B E Kendall; D G MacManus; W I McDonald; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

7.  A population-based study of multiple sclerosis in twins: update.

Authors:  A D Sadovnick; H Armstrong; G P Rice; D Bulman; L Hashimoto; D W Paty; S A Hashimoto; S Warren; W Hader; T J Murray
Journal:  Ann Neurol       Date:  1993-03       Impact factor: 10.422

8.  Unsuspected multiple sclerosis.

Authors:  J J Gilbert; M Sadler
Journal:  Arch Neurol       Date:  1983-09

9.  Subclinical multiple sclerosis.

Authors:  M Morariu; W F Klutzow
Journal:  J Neurol       Date:  1976-07-15       Impact factor: 4.849

10.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.

Authors:  C J De Groot; E Bergers; W Kamphorst; R Ravid; C H Polman; F Barkhof; P van der Valk
Journal:  Brain       Date:  2001-08       Impact factor: 13.501

View more
  5 in total

Review 1.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

2.  CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis.

Authors:  Chandra Deb; Reghann G Lafrance-Corey; William F Schmalstieg; Brian M Sauer; Huan Wang; Christopher L German; Anthony J Windebank; Moses Rodriguez; Charles L Howe
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

3.  Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis.

Authors:  Nicola De Stefano; Maria Laura Stromillo; Francesca Rossi; Marco Battaglini; Antonio Giorgio; Emilio Portaccio; Bahia Hakiki; Gianmichele Malentacchi; Claudio Gasperini; Mario Santangelo; Maria Letizia Bartolozzi; Maria Pia Sormani; Antonio Federico; Maria Pia Amato
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 4.  MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Authors:  Massimo Filippi; Maria A Rocca; Olga Ciccarelli; Nicola De Stefano; Nikos Evangelou; Ludwig Kappos; Alex Rovira; Jaume Sastre-Garriga; Mar Tintorè; Jette L Frederiksen; Claudio Gasperini; Jacqueline Palace; Daniel S Reich; Brenda Banwell; Xavier Montalban; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

Review 5.  Clinical, Radiological and Pathological Characteristics Between Cerebral Small Vessel Disease and Multiple Sclerosis: A Review.

Authors:  Bijia Wang; Xuegang Li; Haoyi Li; Li Xiao; Zhenhua Zhou; Kangning Chen; Li Gui; Xianhua Hou; Rong Fan; Kang Chen; Wenjing Wu; Haitao Li; Xiaofei Hu
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.